BRAF-Mutant Metastatic Melanoma Epidemiology Forecast

 

Key Highlights

• Melanoma of the skin represents 5.6% of all new cancer cases in the US, with rate of new cases of melanoma of the skin was 22.7 per 100,000 per year. The death rate was 2.3 per 100,000. These rates are age-adjusted and based on 2013–2017 cases and 2014–2018 deaths.

 

• According to The Cancer Genome Atlas Network, the BRAF mutation occurs in approximately 50% of cutaneous melanoma and the most common being the V600E (valine to glutamic acid; 70–88%). 

 

• BRAF Mutant Metastatic Melanoma epidemiology is segmented as Total Incident Cases, Type-specific Incident Cases, Stage-specific Incident Cases, Mutation-specific Cases, Age-specific Incident Cases, and Total treated Cases in the BRAF Mutant Metastatic Melanoma epidemiology report.

 

Request for Sample Page of  BRAF Mutant Metastatic Melanoma Epidemiology Report

 

DelveInsight's ‘BRAF Mutant Metastatic Melanoma Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted BRAF Mutant Metastatic Melanoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2021-2034

 

BRAF Mutant Metastatic Melanoma Epidemiology: Disease Understanding

The DelveInsight’s BRAF Mutant Metastatic Melanoma market report gives a thorough understanding of BRAF Mutant Metastatic Melanoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Melanoma is a common skin cancer that arises from the melanin cells within the upper layer of the skin (epidermis) or from similar cells that may be found in moles (nevi). This type of skin cancer may send down roots into deeper layers of the skin, and some of these microscopic roots may spread (metastasize), causing new tumor growths in vital organs of the body.

 

The most prevalent driver in melanoma is mutant BRAF, found in 40–50% of patients with metastatic disease. BRAF mutations occur in other cancers such as colon cancer, papillary thyroid cancer and serous ovarian cancer, but at a frequency much lower than in melanoma.

 

BRAF mutations are found in almost half of all patients with metastatic disease. The most commonly found mutation, the V600E missense mutation, has been proven in clinical trials to respond to BRAF inhibitors such as vemurafenib and dabrafenib. Other V600 BRAF mutations such as V600K have been shown to respond to BRAF inhibitors, while a subset of non-V600 mutations respond to MEK inhibitors.

 

BRAF Mutant Metastatic Melanoma Diagnosis

Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy with BRAF and MEK inhibitors is associated with significant long-term treatment benefit in patients with BRAF V600-mutated melanoma. Therefore, molecular testing for BRAF mutations is a priority in determining the course of therapy.

 

BRAF Mutant Metastatic Melanoma Epidemiology 

The BRAF Mutant Metastatic Melanoma epidemiology section provides insights about historical and current BRAF Mutant Metastatic Melanoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• The disease epidemiology covered in the report provides historical as well as forecasted BRAF Mutant Metastatic Melanoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034.

 

• Melanoma of the skin represents 5.6% of all new cancer cases in the US, with rate of new cases of melanoma of the skin was 22.7 per 100,000 per year. The death rate was 2.3 per 100,000. These rates are age-adjusted and based on 2013–2017 cases and 2014–2018 deaths.

 

• According to The Cancer Genome Atlas Network, the BRAF mutation occurs in approximately 50% of cutaneous melanoma and the most common being the V600E (valine to glutamic acid; 70–88%). 

 

• The disease epidemiology covered in the report provides historical as well as forecasted BRAF Mutant Metastatic Melanoma epidemiology [segmented as Total Incident Cases of Melanoma, Type-specific Incident Cases of Melanoma, Stage-specific Incident Cases of Melanoma, Mutation-specific Cases of Melanoma, Age-specific Incident Cases of Melanoma, and Total treated Cases of Melanoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

 

Country Wise- BRAF Mutant Metastatic Melanoma Epidemiology

This section provides glimpse of the BRAF Mutant Metastatic Melanoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

KOL- Views

To keep up with the current BRAF Mutant Metastatic Melanoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the BRAF Mutant Metastatic Melanoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: BRAF-Mutant Metastatic Melanoma Market
 

Scope of the BRAF Mutant Metastatic Melanoma Epidemiology Report

• The report covers the descriptive overview of BRAF Mutant Metastatic Melanoma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of BRAF Mutant Metastatic Melanoma 
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Melanoma, Type-specific Incident Cases of Melanoma, Stage-specific Incident Cases of Melanoma, Mutation-specific Cases of Melanoma, Age-specific Incident Cases of Melanoma, and Total treated Cases of Melanoma

 

BRAF Mutant Metastatic Melanoma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence BRAF Mutant Metastatic Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for BRAF Mutant Metastatic Melanoma 
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

BRAF Mutant Metastatic Melanoma Report Insights

• Patient Population
• Therapeutic Approaches

 

BRAF Mutant Metastatic Melanoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• BRAF Mutant Metastatic Melanoma Epidemiology Segmentation

 

BRAF Mutant Metastatic Melanoma Report Assessment

• Disease Understanding
• Current Diagosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

 

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of BRAF Mutant Metastatic Melanoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical BRAF Mutant Metastatic Melanoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of BRAF Mutant Metastatic Melanoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about BRAF Mutant Metastatic Melanoma?
• Out of all 7MM countries, which country would have the highest incident population of BRAF Mutant Metastatic Melanoma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the BRAF Mutant Metastatic Melanoma Disease market
• To understand the future market competition in the BRAF Mutant Metastatic Melanoma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for BRAF Mutant Metastatic Melanoma Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the BRAF Mutant Metastatic Melanoma Disease market
• To understand the future market competition in the BRAF Mutant Metastatic Melanoma Disease market